Fenglin Zhang (Feng Zhang)

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 3

Top Topics

Signaling Pathway

Top Venues

Current cancer drug targets

This page only lists publications with an associated author ORCID identifier.

Publications

Yiqi Du, Fenglin Zhang, Panling Xu, Ping Li
Brucine Inhibits Proliferation of Pancreatic Ductal Adenocarcinoma through PI3K/AKT Pathway-induced Mitochondrial Apoptosis. Current cancer drug targets 24 (7) (2024)
Yiqi Du, Fenglin Zhang, Panling Xu, Ping Li
Brucine Inhibits Proliferation of Pancreatic Ductal Adenocarcinoma through PI3K/AKT Pathway-induced Mitochondrial Apoptosis. Current cancer drug targets (2024)
Yiqi Du, Fenglin Zhang, Panling Xu, Ping Li
Brucine Inhibits Proliferation of Pancreatic Ductal Adenocarcinoma through PI3K/AKT Pathway-induced Mitochondrial Apoptosis. Current cancer drug targets 24 (7) (2024)